This website is intended exclusively for healthcare professionals. By clicking Yes, you confirm that you are a registered healthcare professional and understand that the content is not designed for the general public. If you are not a healthcare professional, you must click No and you will be redirected away. Misrepresentation of your status may result in legal consequences.
Skip to main content
This page is updated regularly. Please ensure that you are viewing or using the most up-to-date material by noting the ‘last updated’ information on the relevant material link.
Product resources: Tecentriq® (atezolizumab)
Page last updated: 14 March 2024
Prescribing Information
TECENTRIQ is a prescription medicine used to treat: Adults with a type of lung cancer called non-small cell lung cancer (NSCLC)
Prescribing Information
Patient Leaflet
Tecentriq® (atezolizumab) Patient Alert Card
Product info
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is approved either alone or in combination with targeted therapies and/or chemotherapies, for various forms of metastatic NSCLC, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC), as well as certain types of metastatic urothelial cancer, PD-L1-positive metastatic triple-negative breast cancer and for the treatment of people with BRAF V600 mutation-positive advanced melanoma.
Supporting materials
You will be re-directed to an external website. Roche accepts no responsibility for the content of other websites.
